Effect of Albumin Therapy in Mechanically Ventilated Patients With Sepsis-Associated ARDS
Key facts
- Who runs it
- The Second Affiliated Hospital of Hainan Medical University
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Not yet recruiting
- People taking part
- 260 people, planned
- Starts
- 20 Nov 2026
- Expected to end
- 31 Dec 2027
- Type of study
- Observational, 2 groups
- Record updated
- 17 November 2026
Who can take part
- Age
- 18 years to 85 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 13 criteriaShow less
Who can take part
- Aged 18 years or older
- Clinical diagnosis conforming to the Sepsis-3 consensus criteria
- Diagnosis of acute respiratory distress syndrome (ARDS) fulfilling the European Society of Intensive Care Medicine (ESICM) criteria (mild, moderate, or severe)
- Receiving invasive mechanical ventilation, with an intubation duration ≤ 48 hours at study enrollment
- First admission to the intensive care unit (ICU) ≤ 24 hours prior to enrollment
- Baseline serum albumin concentration ≤ 30 g/L measured at hospital or ICU admission
- Anticipated ICU stay of > 48 hours
Who cannot take part
- Severe burn injury or currently receiving extracorporeal membrane oxygenation (ECMO) support
- Perioperative period of liver transplantation or decompensated liver cirrhosis (Child-Pugh class C)
- Signed Do-Not-Resuscitate (DNR) order, agreement to withhold/withdraw active life-sustaining therapy, or moribund state expected to result in death within 24 hours
- End-stage malignancy or an estimated clinical life expectancy < 3 months
- Known history of severe hypersensitivity or anaphylactic shock to human serum albumin preparations
- Female patients who are pregnant or lactating
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 18 and 85 years old?
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Sepsis-associated acute respiratory distress syndrome (ARDS) is a severe condition where severe infection causes fluid accumulation in the lungs, often requiring invasive mechanical ventilation. Patients with low blood albumin levels are particularly vulnerable to this fluid leakage, leading to prolonged dependence on a ventilator.
Read full original descriptionShow less
This observational study evaluates the association between a targeted human albumin treatment strategy combined with clinically guided fluid removal, and clinical outcomes in adults with sepsis-associated ARDS and low blood albumin levels (≤ 30 g/L).
Conducted at a single hospital, this study compares two groups. The prospective group consists of patients receiving current usual clinical care, where albumin administration and fluid management are determined by the treating clinical team. Their outcomes will be compared to a historical control group of similar patients who received standard care before this targeted albumin management strategy was routinely implemented.
The primary objective is to evaluate whether this targeted albumin strategy is associated with an increase in Ventilator-Free Days at day 28 (VFD-28). VFD-28 reflects both patient survival and successful liberation from the ventilator. The study will also observe secondary outcomes including oxygenation improvement, fluid balance, organ function, mortality, and safety events (e.g., fluid overload or allergic reactions). As an observational study, researchers do not assign treatments; all interventions are based on real-world clinical judgment.
The 2 groups in the trial
- Prospective Observational Cohort
Patients enrolled prospectively receiving current usual clinical care, which includes a targeted human albumin treatment strategy (aiming to maintain serum albumin ≥ 30 g/L) combined with protocolized fluid de-resuscitation. Treatment decisions remain entirely under the discretion of the treating clinical team.
- Historical Control Cohort
Patients identified retrospectively from electronic medical records who received usual clinical care (primarily crystalloid-based fluid management without a targeted albumin protocol) prior to the routine implementation of the targeted albumin strategy.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Prospective Observational Study With Historical Controls Evaluating Human Albumin Therapy in Mechanically Ventilated Patients With Sepsis-Associated Acute Respiratory Distress Syndrome
- Criteria questions
- Built from NCT07857928, who can take part
- Record updated
- 17 November 2026